Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.
Expert Rev Clin Immunol
; 10(2): 207-17, 2014 Feb.
Article
em En
| MEDLINE
| ID: mdl-24410537
ABSTRACT
Interleukin-2 (IL-2) is a cytokine with pleiotropic effects on the immune system. Systemic IL-2 treatment has produced durable responses in melanoma and renal cancer patients, but unfortunately this is effective only in a fraction of patients. Moreover, IL-2 treatment also engenders serious side effects, which limit its clinical utility. It is now appreciated that IL-2 not only stimulates NK and effector T cells but also has a critical role in the generation and maintenance of regulatory T cells, which act to dampen immune responses. Thus, successful immunotherapy of cancers using IL-2 has to address two fundamentally important issues (1) how to limit side effects yet be active where it is needed, and (2) how to preferentially activate effector T cells while limiting the stimulation of Tregs. Strategies are now being developed to address these critical obstacles that may lead to a renaissance of IL-2 therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Células Matadoras Naturais
/
Interleucina-2
/
Linfócitos T Reguladores
/
Linfócitos T Auxiliares-Indutores
/
Imunoterapia
/
Neoplasias
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Rev Clin Immunol
Ano de publicação:
2014
Tipo de documento:
Article